ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?

The article evaluates biopharmaceutical giants AbbVie (ABBV) and Bristol Myers Squibb (BMY), favoring ABBV for its more robust near-term prospects. AbbVie is effectively mitigating revenue declines from Humira's patent expiration through strong growth in new immunology drugs like Skyrizi and Rinvoq, bolstered by strategic acquisitions, and is projected to see a 6.6% sales increase in 2025. In contrast, Bristol Myers Squibb faces significant revenue headwinds from generic competition impacting its legacy portfolio, with 2025 sales estimated to decrease by 4.13%, despite efforts to grow newer assets and recent acquisitions like Karuna Therapeutics. While both companies contend with patent cliffs and acquisition-related debt, ABBV's diversified portfolio and established growth drivers are currently considered more resilient.

Analysis

AbbVie (ABBV) and Bristol Myers Squibb (BMY) present contrasting near-term outlooks as both navigate significant patent cliffs. AbbVie is successfully mitigating the loss of exclusivity for Humira, with strong sales from its next-generation immunology drugs, Skyrizi and Rinvoq, driving a forecasted 6.6% year-over-year sales increase for 2025. This growth is further supported by strategic acquisitions in oncology and neuroscience, although headwinds persist from competitive pressure on Imbruvica and a slowdown in its aesthetics franchise. In contrast, Bristol Myers Squibb faces more immediate top-line pressure, with its legacy portfolio revenue declining 20% in the first quarter due to generic competition, leading to a projected 4.13% sales decrease in 2025. While BMY's 'Growth Portfolio' and recent acquisitions like Karuna Therapeutics show promise for a long-term turnaround, they are not yet sufficient to offset the decline in legacy products. This divergence is reflected in their year-to-date stock performance, with ABBV gaining 11.8% while BMY has lost 11.2%. Despite BMY's more attractive valuation at a 7.60X forward P/E and a higher dividend yield of 5.20% compared to ABBV's 14.76X P/E and 3.4% yield, the downward revisions to 2025 EPS estimates for both companies warrant caution.

Key Decisions for Investors

• Investors prioritizing near-term growth and demonstrated portfolio resilience may find AbbVie's successful transition from Humira to its new growth drivers compelling, despite its higher valuation.
• For value-focused investors, Bristol Myers Squibb presents a potential turnaround opportunity at a significant valuation discount and a higher dividend yield, but this comes with considerable risk tied to its projected revenue decline and dependence on the uncertain ramp-up of its newer assets.
• Monitor the execution of both companies' M&A strategies and their substantial debt loads, as well as the trajectory of BMY's 'Growth Portfolio' against its legacy drug erosion and the performance of ABBV's non-immunology franchises.